The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 09, 2023
Filed:
Nov. 13, 2020
Applicant:
University of Maryland, Baltimore, Baltimore, MD (US);
Inventors:
Lai-Xi Wang, Ellicott City, MD (US);
Wei Huang, Shanghai, CN;
Assignee:
UNIVERSITY OF MARYLAND, BALTIMORE, Baltimore, MD (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); C07K 14/47 (2006.01); A61K 47/68 (2017.01); C12N 1/20 (2006.01); C07K 16/28 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); C12N 9/24 (2006.01); C12P 21/00 (2006.01); A61P 31/18 (2006.01); C12R 1/46 (2006.01);
U.S. Cl.
CPC ...
C07K 14/473 (2013.01); A61K 47/6849 (2017.08); A61K 47/6867 (2017.08); A61P 31/18 (2018.01); A61P 35/00 (2018.01); C07K 14/4725 (2013.01); C07K 16/00 (2013.01); C07K 16/18 (2013.01); C07K 16/2809 (2013.01); C07K 16/2887 (2013.01); C12N 1/20 (2013.01); C12N 1/205 (2021.05); C12N 9/2402 (2013.01); C12P 21/005 (2013.01); C12Y 302/01096 (2013.01); C07K 2317/10 (2013.01); C07K 2317/14 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/72 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C12R 2001/46 (2021.05);
Abstract
The present invention provides for recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. Such recombinant Endo-S mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain to provide different antibody glycoforms carrying structurally well-defined Fc N-glycans.